Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Intestinal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Intestinal Neoplasm

Cancer Family

Intestinal Neoplasm

CI-CAN-00000209Explore in graph →

Non-malignant1,892 active trials21 approved drugs383 evidence items

NCIt: C3141
MeSH: D007414

Overview
Statistics
Survival
Genomics28
Variants & evidence383
Drugs80
Trials9155
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (371)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 301–325 of 371 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
· Clin Cancer Res · 2013 · PMID 23434733 · validated civic_curation pubmed
A novel K-ras mutation in colorectal cancer. A case report and literature review.
· Anticancer Res · 2009 · PMID 19661358 · validated civic_curation pubmed
Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.
· Ann Oncol · 2016 · PMID 27022066 · validated civic_curation pubmed
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
· Ann Oncol · 2015 · PMID 25669829 · validated civic_curation pubmed
A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib.
· Oncologist · 2020 · PMID 32162810 · validated civic_curation pubmed
KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.
· Cureus · 2016 · PMID 27004155 · validated civic_curation pubmed
Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.
· J Pathol · 2014 · PMID 25111426 · validated civic_curation pubmed

Showing 301–325 of 371 publications

← Previous
1
…
12
13
14
15
Next →

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.

· Mod Pathol · 2020 · PMID 31375766 · validated civic_curation pubmed

TumorFusions: an integrative resource for cancer-associated transcript fusions.

· Nucleic Acids Res · 2018 · PMID 29099951 · validated civic_curation pubmed

A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.

· Cancer Res · 2013 · PMID 23539443 · validated civic_curation pubmed

Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells.

· Tumour Biol · 2013 · PMID 23188704 · validated civic_curation pubmed

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

· Sci Transl Med · 2011 · PMID 21900593 · validated civic_curation pubmed

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.

· Mol Cancer · 2014 · PMID 24894453 · validated civic_curation pubmed

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

· Cell Rep · 2014 · PMID 25199829 · validated civic_curation pubmed

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

· Cell Rep · 2014 · PMID 24685132 · validated civic_curation pubmed

HER2 activating mutations are targets for colorectal cancer treatment.

· Cancer Discov · 2015 · PMID 26243863 · validated civic_curation pubmed

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.

· Oncotarget · 2016 · PMID 27167191 · validated civic_curation pubmed

Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.

· Cancer Biol Ther · 2014 · PMID 24642870 · validated civic_curation pubmed

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

· Cancer Res · 2010 · PMID 20570890 · validated civic_curation pubmed

A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.

· Cancer Cell · 2013 · PMID 23845441 · validated civic_curation pubmed

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

· Cancer Res · 2012 · PMID 22180495 · validated civic_curation pubmed

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

· J Clin Oncol · 2008 · PMID 18202412 · validated civic_curation pubmed

A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.

· Cancer Res · 2012 · PMID 22440753 · validated civic_curation pubmed

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

· Int J Cancer · 2015 · PMID 25242168 · validated civic_curation pubmed

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.

· Cell Death Dis · 2014 · PMID 25210794 · validated civic_curation pubmed